Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manolo D'Arcangelo

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Biologics : Targets & Therapy|March 16, 2013
Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancerManolo D'Arcangelo, Federico Cappuzzo
Expert Review of Anticancer Therapy|April 27, 2013
Erlotinib in the first-line treatment of non-small-cell lung cancerManolo D'Arcangelo, Federico Cappuzzo
ISRN Molecular Biology|July 12, 2016
K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValueManolo D'Arcangelo, Federico Cappuzzo
Biologics : Targets & Therapy|May 3, 2014
Clinical and comparative utility of afatinib in non-small cell lung cancerManolo D'Arcangelo, Fred R Hirsch
Future Oncology (London, England)|July 11, 2018
New options on the horizon for nononcogene addicted non-small-cell lung cancerLuca Paglialunga, Serena Ricciardi, Manolo D'Arcangelo
Biomarkers in Medicine|October 7, 2015
The use of circulating biomarkers in early clinical trials in patients with cancerManolo D'Arcangelo, Jane Margetts, Alastair Greystoke
Future Oncology (London, England)|May 8, 2013
Rare mutations in non-small-cell lung cancerManolo D'Arcangelo, Armida D'Incecco, Federico Cappuzzo
Current Opinion in Oncology|February 7, 2013
The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancerManolo D'Arcangelo, Murry W Wynes, Fred R Hirsch
Drugs|June 21, 2012
Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutationTony S K Mok, Manolo D'arcangelo, Raffaele Califano
Journal of Clinical Pharmacology|December 29, 2022
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid TumorsMichael J Hanley, Manolo D'Arcangelo, Enriqueta Felip, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Biologics : Targets & Therapy|March 16, 2013
Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancerManolo D'Arcangelo, Federico Cappuzzo
Expert Review of Anticancer Therapy|April 27, 2013
Erlotinib in the first-line treatment of non-small-cell lung cancerManolo D'Arcangelo, Federico Cappuzzo
ISRN Molecular Biology|July 12, 2016
K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValueManolo D'Arcangelo, Federico Cappuzzo
Biologics : Targets & Therapy|May 3, 2014
Clinical and comparative utility of afatinib in non-small cell lung cancerManolo D'Arcangelo, Fred R Hirsch
Future Oncology (London, England)|July 11, 2018
New options on the horizon for nononcogene addicted non-small-cell lung cancerLuca Paglialunga, Serena Ricciardi, Manolo D'Arcangelo
Biomarkers in Medicine|October 7, 2015
The use of circulating biomarkers in early clinical trials in patients with cancerManolo D'Arcangelo, Jane Margetts, Alastair Greystoke
Future Oncology (London, England)|May 8, 2013
Rare mutations in non-small-cell lung cancerManolo D'Arcangelo, Armida D'Incecco, Federico Cappuzzo
Current Opinion in Oncology|February 7, 2013
The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancerManolo D'Arcangelo, Murry W Wynes, Fred R Hirsch
Drugs|June 21, 2012
Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutationTony S K Mok, Manolo D'arcangelo, Raffaele Califano
Journal of Clinical Pharmacology|December 29, 2022
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid TumorsMichael J Hanley, Manolo D'Arcangelo, Enriqueta Felip, et al.
Pageof 3